PlaqueTec
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Maia Building B270 Babraham Research Cam...Phone Number
+44 1480832930Website
www.plaquetec.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About PlaqueTec
PlaqueTec is at the forefront of developing biomarker-based personalized medicine strategies for the prevention, diagnosis, and treatment of Coronary Artery Disease (CAD), which is the leading cause of death globally. The company utilizes its innovative Liquid Biopsy System to profile the underlying biology of CAD and build disease-specific cohorts. By identifying new drug targets, PlaqueTec aims to inspire a new era of precision medicine for millions of patients affected by CAD. Their research and approach are designed to transform the landscape of cardiovascular health.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PlaqueTec your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if PlaqueTec had a recent Job posting/layoffs
Earning: See what the market has to say on PlaqueTec recently announced quarterly report
Check out if PlaqueTec is spiking on competitors!
Funding: Get notified immidiatlly once PlaqueTec has new funding data
Congratulate Masked Content for being promoted to Masked Content at PlaqueTec
PlaqueTec, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when PlaqueTec launches new products
Check if PlaqueTec has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at PlaqueTec
Find 3 more new buyers
Compare Similar Companies to PlaqueTec
Compare insights from companies similar to PlaqueTec, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PlaqueTec
<$5M
1-10
Private
$13M
2008
N/A
Company Profile Activity
Activity Insights
PlaqueTec is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PlaqueTec is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PlaqueTec.
PlaqueTec financials insights
Gather financial insights about PlaqueTec, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$8M
2026
Other Financing Round
$5M
PlaqueTec Tech Stack
A closer look at the technologies used by PlaqueTec
Most Recent Scoops
Funding
Funding
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
PlaqueTec News & Media
PlaqueTec secures $5m investment to advance novel cardiovascular disease data platform
Explore the latest Scottish deals with insights from our Edinburgh team, advising on transactions worth over £1.5bn globally.PlaqueTec Raises £6.4M in Funding
PlaqueTec, a Cambridge, UK-based company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), raised £6.4M in funding. The round was led by Lord Moynihan of Chelsea alongside the Future Fund, with support from existing investors. The company intends to use the funds to support its ongoing Biopattern trial, designed to improve understanding of CAD […] The post PlaqueTec Raises £6.4M in Funding appeared first on FinSMEs.PlaqueTec recruits first ten patients in BIOPATTERN trial
CAMBRIDGE, England--(BUSINESS WIRE)--PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD. The trial has been designed to improve understanding of the pathobiology of atherosclerotic cardiovascular diseases (ACVD) and howAOBiome Therapeutics Announces the Expansion of its Board of Directors
CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding PlaqueTec
Sign Up For FreeTo access detailed company insights
PlaqueTec is at the forefront of developing biomarker-based personalized medicine strategies for the prevention, diagnosis, and treatment of Coronary Artery Disease (CAD), which is the leading cause of death globally. The company utilizes its innovative Liquid Biopsy System to profile the underlying biology of CAD and build disease-specific cohorts... Read More
